Minimally Invasive Knee Procedure Offers Lasting Relief for Osteoarthritis
- A minimally invasive procedure targeting abnormal blood vessels in the knee reduced chronic osteoarthritis pain and improved mobility for 80% of patients followed for 12 months, sciencedaily.com reported.
- Osteoarthritis affects more than 365 million adults worldwide as the world's most common form of arthritis and a major cause of disability.
- Genicular artery embolization approaches this pain from a different angle by targeting abnormal blood vessels that develop around the inflamed joint.
A minimally invasive procedure targeting abnormal blood vessels in the knee reduced chronic osteoarthritis pain and improved mobility for 80% of patients followed for 12 months, sciencedaily.com reported. The technique, known as genicular artery embolization, offers a potential alternative for individuals who have exhausted conservative treatments but cannot or do not want to undergo joint replacement surgery.
Treating Inflammation by Blocking Abnormal Vessels
Osteoarthritis affects more than 365 million adults worldwide as the world’s most common form of arthritis and a major cause of disability. The condition develops as protective cartilage deteriorates, while inflammation, tissue changes, and sensitized pain-signaling nerves add to persistent discomfort.
Genicular artery embolization approaches this pain from a different angle by targeting abnormal blood vessels that develop around the inflamed joint. These vessels multiply within the synovium, contributing to inflammation and encouraging sensory nerves to transmit pain signals. During the procedure, an interventional radiologist guides a thin catheter into an artery and injects microscopic particles to block selected vessels while preserving normal circulation.
For the study published in the journal Radiology, researchers examined rapidly resorbable, gelatin-based microspheres engineered to dissolve within hours. Florian Nima Fleckenstein, deputy head of Interventional Radiology Campus Mitte at Charité — Universitätsmedizin Berlin, explained the approach.
By reducing both inflammation and pain, GAE with resorbable microspheres may be the first procedure that alters the course of the disease, slowing its progression.
Florian Nima Fleckenstein
Clinical Trial Results from July to November 2024
Researchers evaluated the approach in a prospective single-center study involving 194 patients with osteoarthritis-related knee pain. The participants included 114 women and 80 men, with a median age of 69 years and a body mass index of 28.4. All participants had continued to experience symptoms for at least three months despite conventional care like physical therapy and anti-inflammatory medications.
The procedures took place between July and November 2024. Forty-five participants had osteoarthritis in both knees and received two separate treatments within four weeks, resulting in 239 total procedures performed using real-time fluoroscopy imaging. All procedures were technically successful.
Safety findings showed no moderate or severe adverse events. Mild, temporary complications occurred in 6.7% of procedures, including brief skin discoloration and superficial blood collection near the catheter site, all resolving without lasting issues.
Pain Scores and Functional Improvements Over Twelve Months
Patient follow-up rates remained at 94% at six weeks, 89% at three months, 89% at six months, and 79% at 12 months. Median pain scores on a 0-to-10 Numeric Rating Scale dropped from 7 before treatment to 4 at six weeks, declining to 3 by six months and holding steady at that level through the 12-month mark.
Improvements also appeared in the Knee Injury and Osteoarthritis Outcome Score categories. Median scores for daily activities climbed from 53 to 71.5, while sports and recreation scores rose from 15 to 36. Symptom scores increased from 51 to 68, pain scores moved from 44 to 65, and quality of life scores rose from 19 to 40.
At the one-year follow-up, 80% of assessed participants exceeded the established threshold for clinically meaningful pain relief. Fleckenstein noted the real-world nature of the findings.
We believe these results carry real weight because they come from real-world data. With this broad, inclusive study design, our participants are exactly the patients that physicians encounter every day in their practices.
Florian Nima Fleckenstein
Broader Research Context and Unresolved Questions
Other recent studies have explored similar embolization techniques with varying conclusions. A randomized study published in Clinical Radiology in 2026 compared genicular artery embolization with standard care in 50 patients, reporting a 72.7% pain improvement in the embolization group after one year compared to 24.2% for standard care alone, though that trial used polyvinyl alcohol particles.
However, other investigations have raised questions regarding the specific mechanism. A randomized, sham-controlled study published in European Radiology in April 2026 followed 58 patients for 12 months and found no statistically significant difference in pain reduction between embolization and sham treatment groups, nor did MRI scans show significant reductions in joint inflammation.
Furthermore, an analysis in the September 2026 issue of the European Journal of Radiology examined 22 studies involving 633 patients and found no significant advantage over sham procedures when combining three randomized trials. A separate June 2026 analysis of 45 studies covering 2,205 patients documented improvements in pain and function but rated the overall certainty of the evidence as low or very low.